Abcam, ab245730, Anti-TdT antibody [SP150] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TDT antibody. Carrier free. Suitable for IHC-P, WB, Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:SP150,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:Flow Cyt (Intra), WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab245730 is the carrier-free version of
ab183341
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A/G, Purification notes-Purified from TCS by protein A/G., Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The target protein TdT also known as terminal deoxynucleotidyl transferase or DNTT is an enzyme with a mass of approximately 58 kDa. TdT is specifically expressed in the thymus and bone marrow during early B and T lymphocyte development. This enzyme adds nucleotides to the 3’ ends of DNA contributing to the diversity of the immune response by introducing variability at the junctions of gene segments.
Biological function summary
Terminal deoxynucleotidyl transferase plays an important role in the adaptive immune system. By adding random nucleotides to the V(D)J regions during the development of T and B cells it enhances the variability of antigen receptors. Although TdT does not form part of a larger protein complex its activity directly influences the effectiveness of antigen recognition by lymphocytes important for immune surveillance and response.
Pathways
Terminal deoxynucleotidyl transferase fits into the V(D)J recombination pathway which is essential for the assembly of diverse antigen receptor genes in immature lymphocytes. This enzyme works in conjunction with proteins like RAG1/RAG2 which initiate the DNA cleavage process necessary for recombination and with DNA ligase IV for the joining stage. Enhanced diversity generated by TdT's activity substantiates an effective and adaptable immune response.
TdT is associated with lymphoid malignancies such as acute lymphoblastic leukemia (ALL) where its expression acts as a diagnostic marker. Overexpression or dysregulation of TdT often found in these leukemias correlates with abnormal lymphocyte proliferation. TdT involvement in these disorders is linked to abnormal p53 pathways as p53 mutation frequently occurs alongside abnormal TdT activity suggesting a connection to cellular growth and survival dysregulation in affected cells.